Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

D K Pleskow ¹, H J Berger , J Gyves

⁰New England Deaconess Hospital, Boston, Massachusetts.

Annals of Internal Medicine +

|

May 1, 1989

View abstract on PubMed

Summary

The CA19-9 blood test shows utility in diagnosing pancreatic cancer, demonstrating higher sensitivity and specificity than other serologic markers. This makes it a valuable tool for patients with suspected pancreatic disorders.

Area Of Science

Oncology
Biomarkers
Diagnostic Medicine

Background

Pancreatic cancer diagnosis often relies on imaging and invasive procedures.
There is a need for reliable, non-invasive serologic markers for early detection.
CA19-9 is a known tumor-associated antigen, but its diagnostic utility requires further validation.

Purpose Of The Study

To evaluate the diagnostic accuracy of the serum marker CA19-9.
To compare CA19-9 with other serologic markers for pancreatic cancer.
To determine the utility of CA19-9 in patients with suspected pancreatic disorders.

Main Methods

A blinded study analyzed frozen serum samples from 261 patients.
Serum samples were collected during diagnostic evaluation and assayed for CA19-9 levels.
Results were compared with earlier determinations of other potential pancreatic cancer markers.

Main Results

CA19-9 assay showed 70% sensitivity and 87% specificity for pancreatic cancer.
Median CA19-9 level in cancer patients was 349 u/mL (normal <70 u/mL).
Positive predictive value was 59% and negative predictive value was 92%.

Conclusions

CA19-9 is a more sensitive and specific serologic marker for pancreatic cancer compared to others.
CA19-9 testing is a useful diagnostic aid in patients with suspected pancreatic disease.
The marker's utility is confirmed in a diverse patient population within a university teaching hospital setting.

Related Concept Videos